{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:13:47Z","timestamp":1783660427325,"version":"3.55.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While the long-term cardiorenal benefits of finerenone have been established in landmark clinical trials, its immediate impact on hemodynamic parameters in routine clinical practice remains to be fully characterized. This study aimed to evaluate the real-world acute effects of finerenone on blood pressure (BP) and heart rate (HR) in hospitalized patients with type 2 diabetes (T2D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective observational study of patients with T2D who were initiated on finerenone as part of standard clinical care. Patients were grouped into five cohorts based on the day of treatment initiation (Day 1 to Day 5). We monitored morning (a.m.) and afternoon (p.m.) systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) daily for 7 days. Baseline characteristics, including urinary albumin-to-creatinine ratio (UACR), serum potassium, and renin-angiotensin-aldosterone system (RAAS) markers, were assessed to reflect the real-world population\u2019s heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this real-world cohort, finerenone was mainly prescribed to patients with notably high UACR (average grade III; p &amp;lt; 0.0001 compared to non-users), indicating its targeted use for high-risk kidney patients. Despite a complex background of intensive therapies\u2014including ARBs (90.6%), CCBs (84.6%), and SGLT-2 inhibitors (91.4%)\u2014adding finerenone was linked to significant decreases in both SBP and DBP. Daily detailed analysis showed that the largest BP reductions often occurred within the first 24\u201348 hours of treatment (p &amp;lt; 0.05 to p &amp;lt; 0.0001), across various treatment groups. Additionally, heart rate (HR) remained stable during the initial days of therapy. The distribution of background medications stayed consistent during finerenone treatment, suggesting that the hemodynamic improvements were not due to changes in other antihypertensive medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This real-world evidence indicates that finerenone was associated with antihypertensive effects in hospitalized T2D patients with albuminuria. Its ability to substantially reduce BP and stabilize HR shortly after hospitalization, despite concurrent standard therapies, underscores its practical utility in managing hypertension.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1878697","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:25:33Z","timestamp":1783657533000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hemodynamic effects of finerenone on blood pressure and heart rate in hospitalized patients with type 2 diabetes: a real-world study"],"prefix":"10.3389","volume":"17","author":[{"given":"Song","family":"Wen","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center","place":["Shanghai, China"]},{"name":"Fudan Zhangjiang Institute","place":["Shanghai, China"]},{"name":"Sports-Medicine Integration Chronic Disease Rehabilitation Center, Fudan University, Pudong Medical Center","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Yun","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanju","family":"He","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiucai","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijiao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center","place":["Shanghai, China"]},{"name":"Sports-Medicine Integration Chronic Disease Rehabilitation Center, Fudan University, Pudong Medical Center","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoxun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxiang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[{"name":"Sports-Medicine Integration Chronic Disease Rehabilitation Center, Fudan University, Pudong Medical Center","place":["Shanghai, China"]},{"name":"Department of Rheumatology, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyu","family":"Li","sequence":"additional","affiliation":[{"name":"Sports-Medicine Integration Chronic Disease Rehabilitation Center, Fudan University, Pudong Medical Center","place":["Shanghai, China"]},{"name":"Department of Surgery, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center","place":["Shanghai, China"]},{"name":"Sports-Medicine Integration Chronic Disease Rehabilitation Center, Fudan University, Pudong Medical Center","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.7326\/annals-24-01926","article-title":"Evaluation and management of chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline","volume":"178","author":"Madero","year":"2025","journal-title":"Ann Intern Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7326\/l23-0070","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2025.05.007","article-title":"Exploring inflammatory and fibrotic mechanisms driving diabetic nephropathy progression","volume":"84","author":"Ansari","year":"2025","journal-title":"Cytokine Growth Factor Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf225","article-title":"Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease","volume":"46","author":"Kobayashi","year":"2025","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-06031-1","article-title":"Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists","volume":"67","author":"Savarese","year":"2024","journal-title":"Diabetologia"},{"key":"B9","doi-asserted-by":"publisher","first-page":"E531","DOI":"10.1152\/ajpendo.00022.2023","article-title":"Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease","volume":"324","author":"Yao","year":"2023","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41440-018-0158-6","article-title":"Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease","volume":"42","author":"Nishiyama","year":"2019","journal-title":"Hypertens Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41574-025-01171-3","article-title":"Mechanisms of diabetic kidney disease and established and emerging treatments","volume":"22","author":"Martinez Leon","year":"2026","journal-title":"Nat Rev Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27021097","article-title":"Inflammation and diabetic kidney disease","volume":"27","author":"Zhang","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.08.054","article-title":"Pharmacologic treatment of heart failure with reduced ejection fraction: an updated systematic review and network meta-analysis","volume":"86","author":"van Essen","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11906-019-0924-0","article-title":"Eplerenone versus spironolactone in resistant hypertension: an efficacy and\/or cost or just a men's issue","volume":"21","author":"Manolis","year":"2019","journal-title":"Curr Hypertens Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem"},{"key":"B17","doi-asserted-by":"publisher","first-page":"9641","DOI":"10.1038\/s41467-025-64640-3","article-title":"Finerenone versus spironolactone in patients with chronic kidney disease and type 2 diabetes: a target trial emulation","volume":"16","author":"Wang","year":"2025","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2024.11.008","article-title":"Retinal vessel analysis to assess microvascular function in the healthy eye: a systematic review on the response to acute physiological and pathological stressors","volume":"70","author":"Van Eijgen","year":"2025","journal-title":"Surv Ophthalmol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.s258593","article-title":"Dapagliflozin activates neurons in the central nervous system and regulates cardiovascular activity by inhibiting SGLT-2 in mice","volume":"13","author":"Nguyen","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.s312527","article-title":"An overview of similarities and differences in metabolic actions and effects of central nervous system between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose co-transporter-2 inhibitors (SGLT-2is)","volume":"14","author":"Wen","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2014.08.004","article-title":"Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure","volume":"3","author":"Dei Cas","year":"2015","journal-title":"JACC Heart Fail"},{"key":"B24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12902-025-01985-2","article-title":"The effects of non-insulin anti-diabetic medications on the diabetic microvascular complications: a systematic review and meta-analysis of randomized clinical trials","volume":"25","author":"Wen","year":"2025","journal-title":"BMC Endocr Disord"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e25739","DOI":"10.1161\/HYPERTENSIONAHA.125.25739","article-title":"Finerenone improves albuminuria via MR-TRPC signaling in diabetic kidney disease","volume":"83","author":"Iwakura","year":"2026","journal-title":"Hypertension"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.s557805","article-title":"The renal micro-vasculopathy and systemic aldosterone-renin ratio (ARR) in type 2 diabetic patients-a retrospective real-world study","volume":"18","author":"Wen","year":"2025","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26188829","article-title":"Aldosterone: From essential tubular regulator to pathological driver-physiology, disease, and therapeutic advances","volume":"26","author":"Strizzi","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.70075","article-title":"Finerenone in chronic kidney disease: a comprehensive review of mechanisms, efficacy and safety","volume":"41","author":"Hu","year":"2025","journal-title":"Diabetes Metab Res Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70026","article-title":"CONFIDENCE in the safety and efficacy of dual therapy with an SGLT-2 inhibitor and finerenone in patients with chronic kidney disease and type 2 diabetes","volume":"27","author":"Georgianos","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1702257","article-title":"Comparative safety profiles of spironolactone, eplerenone, and finerenone: a pharmacovigilance study based on FAERS data from 2004 to 2024","volume":"16","author":"Ji","year":"2025","journal-title":"Front Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr170","article-title":"Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes","volume":"32","author":"Albaghdadi","year":"2011","journal-title":"Eur Heart J"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.01434","article-title":"Mineralocorticoid receptor-dependent impairment of baroreflex contributes to hypertension in a mouse model of primary aldosteronism","volume":"10","author":"Shi","year":"2019","journal-title":"Front Physiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics16040566","article-title":"HbA1c-based metabolic stratification: a retrospective study of clinical and biological differences across normoglycemic, prediabetic, and diabetic subjects","volume":"16","author":"Popoviciu","year":"2026","journal-title":"Diagnostics (Basel)"},{"key":"B36","article-title":"Clinicopathological evaluation of Moyamoya disease. Case report and review of literature","volume":"123","author":"Pop","year":"2025","journal-title":"Romanian J Military Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1878697\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:25:33Z","timestamp":1783657533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1878697\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":36,"alternative-id":["10.3389\/fendo.2026.1878697"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1878697","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"1878697"}}